All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SOTALOL HCI
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $69.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 26, 2020
Details:
This significant raise will support Hyloris’ strategy and will be used for the development of existing portfolio of product candidates, establishment of a commercial team in the United States, to fund the expansion of the pipeline, as well as for general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alprostadil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Advanz Pharma
Deal Size: $98.0 million Upfront Cash: $84.0 million
Deal Type: Agreement March 06, 2020
Details:
The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.